Case in Point
Disseminated Histoplasmosis to the Brain
Tareq M. Abu Salah, MD
More
Barriers to Treatment Adherence in Patients with Type 2 Diabetes: A Review
Marcia A. Johnson, RN, DNP, APRN-BC and Janis Davidson, RN, PhD, APRN-BC
More
Models for Implementing Buprenorphine Treatment in the VHA
Adam J. Gordon, MD, MPH, Cynthia M.A. Geppert, MD, PhD, MPH, Andrew Saxon, MD, Ann Cotton, PsyD, Timothy Bondurant, MD, Margaret Krumm, BA, Mary Pat Acquaviva, PA, and Jodie Trafton, PhD
More
| CME Exam
Editorial
Hepatocellular Carcinoma—Implications for the VA
Samuel B. Ho, MD
More
| |
Drug Monitor
• Hydromorphone vs. Morphine for Older Adults
• Combination Therapy for BP Reduction
More
Federal Health Matters
• Gould and Duckworth Fill VA Positions as Kussman Retires
• VA Reports More Infections With Possible Links to Endoscopic Errors
• Article Calls for New DoD/VA Approach to Mild TBI
More
Patient Information
Living with Liver Cancer
More
Reader Feedback
• Don’t Drive Wedges Between Pharmacists and Other Practitioners
More
Managing Advanced Hepatocellular Carcinoma
This supplement to Federal Practitioner on hepatocellular carcinoma (HCC), supported by a grant from Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc., was developed with the aim of helping primary care providers in federal practice (especially those within the VA health care system) provide the highest quality care to their patients who are at risk for or have been diagnosed with HCC. It is our hope that, after reading this supplement, you will be better prepared to: - Identify patients at risk for HCC and initiate recommended screening and surveillance measures.
- Recognize abnormal screening results, order appropriate diagnostic tests, and interpret the results of these tests.
- Understand the strengths and weaknesses of the various HCC staging systems currently in use and apply them effectively.
- Discuss the options available for treating HCC and their appropriate uses according to distinct patient and disease characteristics.
- Know when to consult with specialists (such as gastroenterologists/hepatologists, radiologists, oncologists, and surgeons); when to refer patients to specialty care; and how to keep the lines of communication open between the multidisciplinary treatment team, the patient, and the family.
- Provide early, effective, and ongoing patient education about all aspects of HCC to patients at risk and those who have been diagnosed with the disease.
More
|
